As of Aug 27
| 0.00 / 0.00%|
The 4 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 31.50, with a high estimate of 87.41 and a low estimate of 29.00. The median estimate represents a +143.81% increase from the last price of 12.92.
The current consensus among 4 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.